Summary
Crown Bioscience Inc (Crown Bioscience) is a pharmaceutical company that provides drug discovery and development services. The company offers in vivo and in vitro research reagents. It offers preclinical contract research services in areas of oncology and metabolic disease. Crown Bioscience’s oncology services comprise oncology databases, ex vivo services, human surrogate trials, in vitro services, in vivo services, preclinical formulations, translational research, and drug discovery services. The company provides metabolic disease services such as CVMD databases, and ex vivo services. It has presence in the US, the UK, China and Taiwan. Crown Bioscience is headquartered in Santa Clara, California, the US.
Crown Bioscience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Crown Bioscience Inc, Medical Devices Deals, 2011 to YTD 2017 10
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Crown Bioscience Acquires PDX Business Unit from Molecular Response 13
Venture Financing 13
CBT Pharma Raises USD5 Million in Seed Financing 13
Crown Bioscience Raises Funds in Venture Financing 14
Crown Bioscience Raises USD27 Million in Series D Financing 15
Crown Bioscience Secures US$29 Million In Series C Venture Financing 15
Partnerships 17
Crown Bioscience and Jackson Lab Enter into Agreement 17
Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 17
Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 18
Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 19
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 19
Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 20
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 21
Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 22
Licensing Agreements 23
Crown Bioscience Enters into Licensing Agreement with University of York 23
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 24
Equity Offering 24
Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 24
Crown Bioscience Plans to Raise Funds through IPO 25
Acquisition 26
Crown Bioscience Acquires PreClinOmics 26
Crown Bioscience Acquires Preclinical Oncology Services 26
Crown Bioscience Inc - Key Competitors 28
Key Employees 29
Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Strategy And Business Planning 31
Jul 13, 2017: Crown Bioscience Expands its Life Science Portfolio 31
Jan 26, 2017: CrownBio Announces Expansion of Life Science Division 32
Jan 24, 2017: Crown Bioscience Announces Expansion of Therapeutic Expertise into Inflammation 33
Jan 12, 2017: Crown Bioscience Expands US Capacity for Cardiovascular & Metabolic Disease Research; Partners with New Iberia Research Center of Louisiana 34
Financial Announcements 35
May 19, 2017: Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results 35
Corporate Communications 36
Aug 30, 2016: Crown Bioscience Strategically Strengthens Leadership Team and Names New Chief Financial Officer 36
Product News 37
Oct 13, 2016: Crown Bioscience Announces Further Enhancement of its Technology Platform with New MuBase Models and Features 37
Oct 04, 2016: Crown Bioscience Introduces New In Vivo Platforms for Renal Research 38
Sep 22, 2016: Crown Bioscience Launches New Interactive Feature for XenoBase In Vitro Models 39
Sep 15, 2016: Crown Bioscience Develops Innovative NAFLD Model 40
Jul 07, 2016: Crown Bioscience Announces Launch of OmniScreen Cell Panel Screening Platform 41
Jun 30, 2016: Crown Bioscience Introduces New Recombinant Cell Lines for Oncology Drug Discovery 42
May 19, 2016: Crown Bioscience Launches HuScreen a New High Throughput Service Platform Utilizing the Largest Available Collection of PDX Models 43
May 10, 2016: Crown Bioscience Announces the Establishment of Unique EGFR-mutated Non-Small Cell Lung Cancer Models 44
Apr 26, 2016: Crown Bioscience Launches MuScreen Platform for Evaluating In Vivo Efficacy of Immuno-oncology Agents 45
Apr 05, 2016: Crown Bioscience Strengthens Immuno-oncology Capabilities With HuGEMM 46
Other Significant Developments 47
Apr 19, 2017: Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products 47
Mar 09, 2017: Crown Bioscience Enables Secure Data Real Time Access with the Release of Client Facing Portal 48
Feb 16, 2017: Crown Bioscience Enhances Digital Connectivity with the Release of OncoExpress Technology Platform 49
Aug 18, 2016: Crown Bioscience Center of Excellence for Oncology in San Diego Expands Services 50
Aug 02, 2016: Crown Bioscience Announces the Completion of Over 100 Blood Cancer Studies 51
Jun 16, 2016: Crown Bioscience Announces Strengthening of Global Immuno-Oncology Platform with Immunophenotyping Service Offering 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Tables
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts 1
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Crown Bioscience Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Crown Bioscience Inc, Medical Devices Deals, 2011 to YTD 2017 10
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Crown Bioscience Acquires PDX Business Unit from Molecular Response 13
CBT Pharma Raises USD5 Million in Seed Financing 13
Crown Bioscience Raises Funds in Venture Financing 14
Crown Bioscience Raises USD27 Million in Series D Financing 15
Crown Bioscience Secures US$29 Million In Series C Venture Financing 15
Crown Bioscience and Jackson Lab Enter into Agreement 17
Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 17
Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 18
Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 19
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 19
Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 20
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 21
Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 22
Crown Bioscience Enters into Licensing Agreement with University of York 23
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 24
Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 24
Crown Bioscience Plans to Raise Funds through IPO 25
Crown Bioscience Acquires PreClinOmics 26
Crown Bioscience Acquires Preclinical Oncology Services 26
Crown Bioscience Inc, Key Competitors 28
Crown Bioscience Inc, Key Employees 29
Crown Bioscience Inc, Other Locations 30
Crown Bioscience Inc, Subsidiaries 30List of Figures
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Crown Bioscience Inc, Medical Devices Deals, 2011 to YTD 2017 10
